Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

Brings 20+ years of experience in finance and business operations at both public and private life sciences companies Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RN

10-Q - Bone Biologics Corp (0001419554) (Filer)

8-K - Bone Biologics Corp (0001419554) (Filer)

8-K - Bone Biologics Corp (0001419554) (Filer)

8-K - Bone Biologics Corp (0001419554) (Filer)

424B5 - Bone Biologics Corp (0001419554) (Filer)

8-K - Bone Biologics Corp (0001419554) (Filer)

EFFECT - Bone Biologics Corp (0001419554) (Filer)

S-3 - Bone Biologics Corp (0001419554) (Filer)

10-Q - Bone Biologics Corp (0001419554) (Filer)

DEFA14A - Bone Biologics Corp (0001419554) (Filer)

4 - Bone Biologics Corp (0001419554) (Issuer)

3 - Bone Biologics Corp (0001419554) (Issuer)

4 - Bone Biologics Corp (0001419554) (Issuer)

4 - Bone Biologics Corp (0001419554) (Issuer)

4 - Bone Biologics Corp (0001419554) (Issuer)

4 - Bone Biologics Corp (0001419554) (Issuer)

4 - Bone Biologics Corp (0001419554) (Issuer)

4 - Bone Biologics Corp (0001419554) (Issuer)

3 - Bone Biologics Corp (0001419554) (Issuer)

4 - Bone Biologics Corp (0001419554) (Issuer)

Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics' company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern time. The presentation will be available on the company's website for a period of time here. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can regis

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276771). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for t

Reminder: Management "CEO Chat" with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company's NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. This pilot clinical study will evaluate NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degene

BURLINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, the Company's president and chief executive officer, and Deina Walsh, chief financial officer, will be interviewed by Zacks Small-Cap Research analyst Brad Sorensen, CFA in a "CEO Chat" on June 20th at the Life Science Investor Forum with Virtual Investor Conference hosted by VirtualInvestorConferences.com. The interview will begin at 11:00 a.m. Eastern time and can be viewed here. Investors are encouraged to preregister to expedite participation an

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants have an exercise price of $2.43 per share, are exercisable immediately upon issuance and will expire five years after the date of issuance. H.C. Wainwright & Co. acted as the exclus

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $2.43 per share, will be exercisable immediately upon issuance and will expire five years after the date of issuance. The closing of the offering is expected to occur on or

Bone Biologics Corporation (NASDAQ:BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion. Following Human Research Ethics Committee (HREC) approval last year in Australia for the multicenter, prospective, randomized pilot clinical trial, the Company reports that three hospital sites have been engaged to participate in the pilot clinical trial. This pilot clinical trial will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD). Inclusion criteria include patien

Brings 20+ years of experience in finance and business operations at both public and private life sciences companies Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RN

Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on The Nasdaq Capital Market, but will remain under Nasdaq's discretionary panel monitor until June 28, 2024. Bone Biologics was notified by Nasdaq on Septe

Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company

Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc.  (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC

U.S. stocks traded lower this morning, with the Dow Jones dipping around 400 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.99% to 39,957.30 while the NASDAQ fell 2.08% to 17,622.81. The S&P 500 also fell, dropping, 1.47% to 5,473.80. Check This Out: Jim Cramer Calls Axsome A ‘Double Or Nothing Stock,’ Says SAP Is ‘Incredible’ Leading and Lagging SectorsUtilities shares jumped by 0.3% on Wednesday. In trading on Wednesday, consumer discretionary shares fell by 2.7%. Top Headline Alphabet Inc (NASDAQ:GOOG) posted better-than-expected earnings and sales results for its second quarter. Alphabet reported second-quarter revenue of $84.742